News

Company pays over $81m for allegedly promoting topiramate for unapproved uses

BMJ 2010; 340 doi: 10.1136/bmj.c2848 (Published 27 May 2010)
Cite this as: BMJ 2010;340:c2848

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Zosia Kmietowicz
  1. 1London

    Two subsidiaries of drug giant Johnson & Johnson have agreed to pay fines of more than $81m (£56m; €65m) for allegedly illegal promotion of the epilepsy drug topiramate (Topamax) for psychiatric uses, the US Justice Department announced on 24 May.

    Ortho-McNeil Pharmaceutical LLC, one of the subsidiaries, pleaded guilty to one count of misdemeanour for promoting topiramate for uses that were not approved by the US Food and Drug Administration (FDA) and was ordered to pay a criminal fine of $6.14m.

    The government says that the company promoted topiramate for unapproved uses …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular